Clearside Biomedical Q2 2023 Earnings Report $0.79 -0.07 (-7.82%) As of 03/3/2025 04:00 PM Eastern Earnings HistoryForecast Clearside Biomedical EPS ResultsActual EPS-$0.15Consensus EPS -$0.14Beat/MissMissed by -$0.01One Year Ago EPSN/AClearside Biomedical Revenue ResultsActual Revenue$1.02 millionExpected Revenue$0.21 millionBeat/MissBeat by +$810.00 thousandYoY Revenue GrowthN/AClearside Biomedical Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call ResourcesPress ReleaseCLSD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Clearside Biomedical Earnings HeadlinesClearside Biomedical’s partner in China granted acceptance of arcatus NDAFebruary 21, 2025 | markets.businessinsider.comClearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaFebruary 20, 2025 | globenewswire.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…March 4, 2025 | Investors Alley (Ad)Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trialFebruary 18, 2025 | msn.comJonesResearch sees buying opportunity in Clearside ahead of 2025 updatesFebruary 11, 2025 | markets.businessinsider.comClearside reports progress in wet AMD treatment trialsFebruary 10, 2025 | msn.comSee More Clearside Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email. Email Address About Clearside BiomedicalClearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.View Clearside Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Marvell Technology (3/5/2025)Broadcom (3/6/2025)Costco Wholesale (3/6/2025)JD.com (3/6/2025)Canadian Natural Resources (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
